Neuphoria Therapeutics (NEUP) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on therapies for neuropsychiatric disorders, advancing lead candidate BNC210 for social anxiety disorder and PTSD.

• BNC210 is an oral, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, designed for rapid, non-sedating anxiety relief.

• Pipeline includes early-stage programs for cognitive deficits in Alzheimer's and other CNS conditions, with strategic partnerships including Merck.

• Recently re-domiciled from Australia to Delaware, becoming the successor issuer to Bionomics.

Financial performance and metrics

• Has incurred significant operating losses since inception and expects continued losses for the foreseeable future.

• No revenue generated from product sales to date.

Use of proceeds and capital allocation

• May receive up to $12.5 million from the exercise of a warrant by the selling shareholder.

• Proceeds will fund BNC210 registrational programs, business development, working capital, and general corporate purposes.